Groundbreaking ‘Enteral Ventilation’ Shows Promise in Human Trials

A novel medical technique known as “enteral ventilation,” which involves delivering oxygen rectally, has successfully passed the initial phase of human testing in Japan. This innovative method, which garnered an IgNobel Prize in 2024, aims to assist individuals suffering from blocked airways or severe lung complications. The findings were published on October 20, 2025, in the journal Med.

Dr. Takanori Takebe, a prominent figure in organoid medicine affiliated with both Cincinnati Children’s Hospital Medical Center and the University of Osaka, led the study. He explained that while the preliminary results demonstrate the safety of the procedure, further evaluation is necessary to assess its efficacy in oxygen delivery to the bloodstream.

Understanding Enteral Ventilation

Enteral ventilation is envisioned as a process similar to an enema, where a super-oxygenated liquid is introduced into the colon, allowing oxygen to be absorbed into the bloodstream. The concept draws inspiration from the loach, a fish capable of extracting oxygen from the air through its digestive system, thus surviving in low-oxygen environments.

This approach builds on earlier work by former Cincinnati Children’s researcher Leland Clark, who developed a perfluorocarbon liquid known as Oxycyte. Although Oxycyte was not advanced as an artificial blood substitute, it gained attention in popular culture, notably in the 1989 film The Abyss, which depicted animals “breathing” the liquid.

Study Details and Future Directions

The recent study involved 27 healthy male participants in Japan, who were instructed to retain varying volumes of the perfluorocarbon liquid for a duration of 60 minutes. Of those, 20 participants managed to hold up to 1,500 ml for the entire period. While some reported feelings of abdominal bloating and discomfort, there were no serious adverse events noted.

The next phase of research will focus on administering the oxygenated version of the liquid to determine the optimal volume and duration needed to enhance blood oxygen levels. Dr. Takebe and his team aim to eventually adapt the technology for use in neonatal care. He has also established a company called EVA Therapeutics to pursue this groundbreaking project. The timeline for future clinical trials will largely depend on fundraising efforts.

As this innovative approach progresses through testing, it has the potential to revolutionize emergency treatment for individuals facing respiratory crises, offering hope in scenarios where traditional methods fall short.